Allergic Conjunctivitis - Pipeline Insight, 2024

This “Allergic Conjunctivitis - Pipeline Insight, 2024,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Allergic Conjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Allergic Conjunctivitis Understanding

Allergic Conjunctivitis: Overview

Allergic conjunctivitis is a common, under-appreciated, and largely benign process. It is rarely vision-threatening but can significantly decrease the quality of life for patients. There are three subtypes of simple allergic conjunctivitis: acute, seasonal, and perennial. There is considerable overlap with atopic conjunctivitis (vernal and atopic keratoconjunctivitis) and giant papillary conjunctivitis in both treatment and certain aspects of pathophysiology. As such, these are all considered to be ocular allergies. Initial treatment strategies can be similar, although outcomes and rates of complications vary. The diagnosis is made clinically with a thorough history and classic physical examination findings. If there is any concern based on the history and physical examination, fluorescein staining of the cornea can ensure no corneal abrasion. Laboratory testing is generally not needed, although skin prick or serum allergy testing can help mitigate the disease process by identifying the offending allergens so that they can be avoided if possible. Allergen avoidance is the best way to treat allergic conjunctivitis. In the case of pollen allergies, symptoms are made worse by outdoor activities. Wearing glasses or goggles outdoors can minimize exposure to outdoor allergens. Washing the hair and face can effectively remove these allergens from the surface of the eyes, hair, and skin. Using refrigerated artificial tears can rinse the eye and also remove allergens from the eye. These can provide additional relief when used cold instead of at room temperature. It is also important to avoid rubbing the eyes, as this can make symptoms of allergic conjunctivitis worse.

Allergic Conjunctivitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Allergic Conjunctivitis pipeline landscape is provided which includes the disease overview and Allergic Conjunctivitis treatment guidelines. The assessment part of the report embraces, in depth Allergic Conjunctivitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Conjunctivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Allergic Conjunctivitis.
• In the coming years, the Allergic Conjunctivitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Allergic Conjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Allergic Conjunctivitis treatment market. Several potential therapies for Allergic Conjunctivitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Allergic Conjunctivitis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Allergic Conjunctivitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Allergic Conjunctivitis Emerging Drugs Chapters

This segment of the Allergic Conjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Allergic Conjunctivitis Emerging Drugs

Reproxalap: Aldeyra TherapeuticsReproxalap, an investigational new drug, is a first-in-class small-molecule modulator of RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease. Reproxalap’s mechanism of action has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications. Reproxalap is currently in Phase 3 clinical development as a 0.25% ophthalmic solution for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology.

VSJ-110: Vanda PharmaceuticalsVSJ-110 is a small molecule nanomolar potency CFTR activator. VSJ-110 has shown efficacy in a dry eye model3 and exhibited anti-inflammatory properties in both in vitro and in vivo assays. Vanda entered into a license agreement with UCSF in 2017, under which Vanda acquired an exclusive worldwide license from UCSF to develop and commercialize a portfolio of CFTR activators and inhibitors, including VSJ-110. CFTR activators and inhibitors may have broad applicability in addressing a number of disorders, including chronic dry eye, constipation, polycystic kidney disease, cholestasis, and secretory diarrheas.

Allergic Conjunctivitis: Therapeutic Assessment

This segment of the report provides insights about the different Allergic Conjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Allergic Conjunctivitis

There are approx. 22+ key companies which are developing the therapies for Allergic Conjunctivitis. The companies which have their Allergic Conjunctivitis drug candidates in the most advanced stage, i.e. phase III include, Aldeyra Therapeutics.

Phases

This report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Allergic Conjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Allergic Conjunctivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Allergic Conjunctivitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Allergic Conjunctivitis drugs.

Allergic Conjunctivitis Report Insights

• Allergic Conjunctivitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Allergic Conjunctivitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Allergic Conjunctivitis drugs?
• How many Allergic Conjunctivitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Allergic Conjunctivitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Allergic Conjunctivitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Allergic Conjunctivitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aldeyra Therapeutics
• Vanda Pharmaceuticals
• Noveome Biotherapeutics
• Allakos, Inc.
• Regeneron Pharmaceuticals
• Marinomed Biotech AG
• Eleusis Holdings Ltd
• IACTA Pharmaceuticals
• JW Pharmaceutical
• Nanomerics
• OKYO Pharma
• RAPT Therapeutics
• Allakos
• Sylentis
• Postbiotica
• Stuart Therapeutics
• Oyster Point Pharma
• Bausch Health Companies Inc.
• Marinomed Biotech AG
• ILTOO Pharma
• Emergo Therapeutics
• Immunotek SL
• Roxall Medicina España S.A
• Biomay AG

Key Products

• Reproxalap
• VSJ-110
• ST266
• AK002
• REGN1908-1909
• Budesolv
• IC 270
• OC134
• OK-101
• RPT193
• Lirentelimab
• SYL 116011
• OC-103 AAV
• EM-100
• Tacrosolv
• ILT-101
• Norketotifen
• MM09-MG01
• MM09
• Allergovac Depot
• BM41
• MG01

This product will be delivered within 1-3 business days.